Medicaid Provider Spending

$1.09 trillion in Medicaid claims data, 2018–2024 · 617K+ providers

PERFORMANCE LABORATORIES LLC

NPI: 1245657675 · OKLAHOMA CITY, OK 73102 · Clinical Medical Laboratory · NPI assigned 03/24/2014

$386K
Total Medicaid Paid
41,857
Total Claims
30,685
Beneficiaries
29
Codes Billed
2018-01
First Month
2019-08
Last Month

Provider Details

Authorized OfficialMUSTAFA, SAMIYA (OWNER/CEO)
NPI Enumeration Date03/24/2014

Related Entities

Other providers sharing the same authorized official: MUSTAFA, SAMIYA

ProviderCityStateTotal Paid
PATHWAY DIAGNOSTICS LLC PICAYUNE MS $548K
LAZARUS SERVICES, LLC NEW ORLEANS LA $0.00

Monthly Spending Trend

Yearly Breakdown

YearClaimsTotal Paid
2018 23,146 $191K
2019 18,711 $195K

Billing Codes

CodeDescriptionClaimsBeneficiariesTotal Paid
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 8,688 2,694 $142K
81408 2,049 1,734 $38K
81162 758 747 $35K
81201 1,228 1,217 $29K
81292 1,298 1,286 $24K
81321 1,276 1,264 $22K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 5,659 1,834 $21K
81317 1,262 1,251 $16K
81405 1,310 1,251 $8K
81404 1,243 1,230 $8K
81298 1,315 1,303 $7K
81401 916 904 $5K
81406 1,326 1,267 $4K
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed 1,340 674 $4K
81295 1,315 1,303 $4K
81324 926 921 $3K
81403 1,283 1,250 $2K
81225 847 838 $2K
81226 849 840 $2K
81227 847 838 $1K
81328 851 839 $1K
81231 848 839 $1K
81230 846 837 $1K
81241 851 839 $1K
81240 851 839 $1K
81291 849 837 $1K
81257 950 945 $624.20
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed 34 30 $0.00
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed 42 34 $0.00